Trial Profile
Phase II Trial of Ipilimumab and Nivolumab in Leptomeningeal Metastases
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Meningeal carcinomatosis; Solid tumours
- Focus Therapeutic Use
- 21 Oct 2022 Status changed from active, no longer recruiting to completed.
- 04 Sep 2020 Planned End Date changed from 1 Jan 2024 to 1 Sep 2021.
- 04 Sep 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Sep 2021.